Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities (2010 - 2025)

Rigel Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $122.1 million for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 21.56% year-over-year to $122.1 million in Q4 2025; TTM through Dec 2025 was $122.1 million, a 21.56% decrease from a year earlier, with the FY2025 full-year figure at $122.1 million, down 21.56% from the prior year.
• Total Non-Current Liabilities improved to $122.1 million in Q4 2025 per RIGL's latest filing, from $119.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $158.5 million in Q1 2021 and bottomed at $66.9 million in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $118.6 million (2025), against an average of $118.6 million.
• Across the five-year window, Total Non-Current Liabilities plunged 49.38% in 2022 and surged 62.03% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $84.2 million in 2021, then rose by 25.41% to $105.6 million in 2022, then climbed by 0.28% to $105.9 million in 2023, then surged by 46.98% to $155.7 million in 2024, then decreased by 21.56% to $122.1 million in 2025.
• Per Business Quant, the three latest RIGL Total Non-Current Liabilities figures stand at $122.1 million (Q4 2025), $119.9 million (Q3 2025), and $119.8 million (Q2 2025).